Our current R&D program within the Microbiome field focuses on the development of new culture processes for microbiome strains releasing the full potential of testing and producing such strains in a larger scale. To be able to investigate Mode of Actions of microbiome strains and probiotics, we will develop relevant human cell model systems, e.g. immune models and intestinal models, that in addition will be used for evaluation the interactions between the microbiome and drug substances.
The R&D groups involved in the Microbiome activities are located both at the Bioneer headquarter facilities in Hørsholm and at Bioneer:FARMA located in Copenhagen, ensuring access to key instruments and a broad palette of analytical equipment essential for the R&D program.
Microbiome in Health and Disease
Bioneer will develop new interdisciplinary services, that address the increasing industry need for documentation and understanding of naturally occurring intestinal and probiotic bacteria’s effect on diseases, as well as on drug substance turnover and effects.
Bioneer will establish new culturing procedures for complex microbiomes and intestinal bacteria, derived from feces collected in diseased or healthy individuals. These procedures will aim at upholding diversity and viability, as well as enrichment of specific fractions of isolated microbiomes or single bacterial strains in order to evaluate probiotic potential. Collectively, the new set of skills will lay the basis for new and improved supporting services within in vitro cell models and new microbiome mixtures.
For further information, please contact Kim Holmstrøm, R&D Manager, Molecular Detection by email.
Bioneer will continue to develop Bioneer’s advanced in vitro immune cell models to enable investigation of the interaction between the microbiome and the immune system, relevant organ systems as well as interactions with drug substances. The intestinal system will be the initial complex cell model, consisting of intestinal microbiome components, intestinal barrier cells, and intestinal homing immune cells. The model will be validated with reference pharmaceutical drugs.
Bioneer:FARMA will develop different intestinal models where the effect of pharmaceutical drugs can be evaluated in the presence or absence of a microbiome, as well as the influence on the absorption of the drugs. For instance, a laboratory colon model will be established in collaboration with the University of Copenhagen.
Bioneer:FARMA will develop different formulations of a selected number of probiotic strains, which will be able to protect the bacteria against gastric acid and bile salts, and thereby ensure delivery of the probiotics to the distant end of the small intestines as well as the large intestines. The resulting formulations will, among others, be evaluated in the Dynamic Gastric Model (DGM) located at Bioneer:FARMA.
> Professor Dennis S. Nielsen, University of Copenhagen
Bioneer has an established collaboration with the research group of Prof. Dennis S. Nielsen within Department of Food Science at the University of Copenhagen, Denmark. Professor Nielsen focuses on microbial behavior in complex environments and the association between the mammalian gut microbiome (GM), health and disease. The collaboration with the group will play a key role in some of the coming microbiome R&D activities at Bioneer.
For more information, please contact Head of Bioneer:FARMA Anette Müllertz via email or phone +45 45160444.
> MVA Microbiome Network
Bioneer is an active member of the Medicon Valley Alliance Microbiome Network. Based on the growing interest in microbiome science identified at the Medicon Valley Alliance Microbiome Summit 2017, MVA decided, together with the Technical University of Denmark, Lund University, University of Copenhagen and Novo Nordisk, to initiate a professional network of Danish and Swedish microbiome scientists and business developers working in drug discovery, nutrition and probiotic development.
For more information about the network, press here. For any interest in microbiome collaboration, please contact BD Manager Lovisa M. Sunesson via email or phone +45 45160444.
Klindt-Toldama, S., Larsen, SK., Saaby, L., Olsen, LR., Svenstrup, G., Müllertz, A., Knøchel, S., Heimdal, H., Nielsen, DS., Zielińska, D. (2016) Survival of Lactobacillus acidophilus NCFM® and Bifidobacterium lactis HN019 encapsulated in chocolate during in vitro simulated passage of the upper gastrointestinal tract. LWT 74; 404-410. ScienceDirect
Gad, M., Ravn, P., Søborg, DA., Lund-Jensen, K., Ouwehand, AC., Jensen, SS. (2011) Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol 63(1):93-107. Pubmed
Holmstrøm, K., Collins, MD., Møller, T., Falsen, E., Lawson, PA. (2004) Subdoligranulum variabile gen. nov., sp. nov. from human feces. Anaerobe 10(3):197-203. Pubmed
Lay, C., Rigottier-Gois, L., Holmstrøm, K., Rajilic, M., Vaughan, EE., de Vos, WM., Collins, MD., Thiel, R., Namsolleck, P., Blaut, M., Doré, J. (2005) Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 71(7):4153-5. Pubmed
Create new products and processes
We offer access to essential tools, technology and unique biological resources within cell and molecular biology.